The RCE-6 emits a precisely shaped photonic pulse tuned to the absorption spectrum of rhodopsin and the photosensitive ganglion cells of the human retina, including the modified photoreceptor arrays found in most commercial ocular augmentations. Rather than producing simple flash-blindness through saturation, the Whiteout's pulse chemically depletes the retina's photosensitive compounds and simultaneously overstimulates the optic nerve's signal pathway, producing a cascading neural feedback loop that extends blindness far beyond what simple bright-light exposure would cause. Baseline human targets experience total blindness lasting eight to twenty-five minutes; targets with standard ocular augmentations experience device lockout lasting up to forty minutes as onboard safety systems attempt to reboot fried photoreceptor arrays.

The weapon's targeting system uses a passive infrared rangefinder to shape the photonic pulse into a cone calibrated for the target's estimated eye-level at range, accounting for the natural pupillary dilation of individuals in low-light environments — the conditions in which the Whiteout is most commonly deployed. A secondary spread mode widens the cone to cover a four-meter arc, effective against multiple targets or moving individuals at the cost of reduced per-target duration. The pulse itself is invisible to the human eye during the millisecond of emission but produces a characteristic cyan afterimage in peripheral witnesses.

Helix Biosystems developed the RCE-6 under a joint military contract alongside a companion treatment compound — a rapid rhodopsin restoration agent sold separately at significant markup. The implication that Helix profits from both the weapon and its antidote has not escaped critics, and the company's lobbying against optic augmentation safety standards has drawn sustained attention from watchdog organizations. The weapon is technically classified as a 'non-lethal denial system,' a legal designation that has allowed it to circulate far more widely than its effects arguably warrant.